Purchase this article with an account.
Jesse L. Berry, Rima F. Jubran, Hashem Almarzouki, Simon Bababeygy, A. Linn Murphree; Outcomes of Group D Retinoblastoma Eyes. Invest. Ophthalmol. Vis. Sci. 2011;52(14):2470.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To determine treatment outcomes of Group D retinoblastoma eyes
Retrospective chart review
All patients diagnosed with retinoblastoma and classified as Group D in at least one eye during a ten-year period from January 1, 2000 to December 31, 2009 at Childrens Hospital Los Angeles were included. 107 eyes of 94 patients were included in the study; 44 patients had unilateral disease and 50 had bilateral disease, 13 of which had bilateral Group D disease. 50 of 107 Group D eyes were enucleated primarily. 57 eyes were treated with systemic and local chemotherapy, as well as local consolidation. 27 of 57 eyes (47%) were salvaged with chemotherapy and consolidation therapy. 30 eyes had recurrences; 5 eyes were enucleated and 25 eyes were treated with 36 Gy intensity modulated radiotherapy (IMRT). Of the 25 irradiated eyes, 20 (80%) were salvaged. 5 eyes were enucleated after IMRT treatment. Two patients died from retinoblastoma, 1 from a midline primitive neuroectodermal tumor and the other from CNS metastases without ocular recurrence. Final visual acuity ranged from 20/20 to light perception with 10 eyes having 20/80 vision or better. 4 eyes had 20/200 vision. Mean length of follow-up was 42.6 months.
During a ten-year period, 47 of 57 treated (82%) Group D eyes were salvaged. 47% (27/57) were salvaged with systemic and local chemotherapy alone. 20 of 57 (35%) eyes required IMRT for salvage. In our series, systemic treatment for retinoblastoma even in advanced eyes can salvage a majority of eyes, many with functional vision.
This PDF is available to Subscribers Only